Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation

Daniel N. Marco; Mònica Molina; Ana-María Guio; J.A. Julian; Virginia Fortuna; Virginia-Lucila Fabregat-Zaragoza; María Queralt Salas; Inés Monge‐Escartín; Gisela Riu-Viladoms; Esther Carcelero; Joan Ramón Roma; Noemí Llobet; Jordi Arcarons; María Suárez‐Lledó; Laura Rosiñol; Francesc Fernández‐Avilés; Montserrat Rovira; Merçè Brunet; Carmen Martı́nez

doi:10.3390/ph17050553

Abstract

Tacrolimus (Tac) is pivotal in preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). It has been reported that genetic factors, including

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marco et al. (2024) studied this question.

synapsesocial.com/papers/68e6d971b6db64358765576c https://doi.org/10.3390/ph17050553

View Full Paper

Ask AI

Bookmark

Share

Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation

Abstract

Discussion

Cite This Study

Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation

Abstract

Discussion

Cite This Study

Keep reading

Keep reading